Skip to main content
. 2023 Feb 20;11(2):e006121. doi: 10.1136/jitc-2022-006121

Figure 5.

Figure 5

Profiling of Mutant Imp3-Specific TCR TransgenIC (MISTIC) ACT–treated escape tumors. (A) Variant allele frequency (VAF) of the Imp3 mutation obtained through whole-exome sequencing of GL261 tumors from control or MISTIC ACT–treated moribund mice. Significance by t-test with n=2 for control and n=3 for treated mice. (B) Gene expression for a subset of target genes from GL261 tumors isolated from control or MISTIC ACT–treated moribund mice with expression given in fragments-per-kilobase-million (FPKM). Significance by t-test with n=2 for control and n=3 for treated mice. (C) Representative flow cytometry plots gated on bulk CD8 T cells (left), MISTIC CD8 T cells (middle), or non-MISTIC CD8 T cells (right) in the indicated tumor samples on the day of harvesting from moribund mice.